{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:28:40Z","timestamp":1791296920211,"version":"4.1.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,6,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Natural killer (NK) cells are potent anti-viral and antitumor \u201cfirst responders\u201d endowed with natural cytotoxicity and cytokine production capabilities. To date, attempts to translate these promising biologic functions through the adoptive transfer of NK cells for the treatment of cancer have been of limited benefit. Here we trace the fate of adoptively transferred murine NK cells and make the surprising observation that NK cells traffic to tumor sites yet fail to control tumor growth or improve survival. This dysfunction is related to a rapid down-regulation of activating receptor expression and loss of important effector functions. Loss of interferon (IFN)\u03b3 production occurs early after transfer, whereas loss of cytotoxicity progresses with homeostatic proliferation and tumor exposure. The dysfunctional phenotype is accompanied by down-regulation of the transcription factors Eomesodermin and T-bet, and can be partially reversed by the forced overexpression of Eomesodermin. These results provide the first demonstration of NK-cell exhaustion and suggest that the NK-cell first-response capability is intrinsically limited. Further, novel approaches may be required to circumvent the described dysfunctional phenotype.<\/jats:p>","DOI":"10.1182\/blood-2012-03-415364","type":"journal-article","created":{"date-parts":[[2012,4,28]],"date-time":"2012-04-28T20:30:24Z","timestamp":1335645024000},"page":"5758-5768","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":180,"title":["Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells"],"prefix":"10.1182","volume":"119","author":[{"given":"Saar","family":"Gill","sequence":"first","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrianne E.","family":"Vasey","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alysha","family":"De Souza","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Baker","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron T.","family":"Smith","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holbrook E.","family":"Kohrt","sequence":"additional","affiliation":[{"name":"Oncology, Department of Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mareike","family":"Florek","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Kenneth D.","family":"Gibbs","sequence":"additional","affiliation":[{"name":"The Baxter Laboratory in Genetic Pharmacology, Stanford University, Stanford, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Tate","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[{"name":"Divisions of Blood and Marrow Transplantation and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807502723300_B1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.7150\/jca.2.383","article-title":"Bortezomib treatment to Potentiate the antitumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells.","volume":"2","author":"Lundqvist","year":"2011","journal-title":"J Cancer"},{"key":"2019111807502723300_B2","article-title":"Successful haploidentical hematopoietic cell engraftment using a non-myeloablative preparative regimen including natural killer (NK) cells [abstract].","volume":"112","author":"Cooley","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"12","key":"2019111807502723300_B3","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1182\/blood-2011-01-329508","article-title":"Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high-risk acute myeloid leukemia patients.","volume":"118","author":"Curti","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2019111807502723300_B4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia.","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111807502723300_B5","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N","article-title":"Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma.","volume":"76","author":"Law","year":"1995","journal-title":"Cancer"},{"issue":"12","key":"2019111807502723300_B6","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/j.exphem.2007.08.006","article-title":"Antimyeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.","volume":"35","author":"Alici","year":"2007","journal-title":"Exp Hematol"},{"key":"2019111807502723300_B7","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.4049\/jimmunol.1000652","article-title":"NK cell adoptive transfer combined with ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.","volume":"186","author":"Salagianni","year":"2011","journal-title":"J Immunol"},{"issue":"24","key":"2019111807502723300_B8","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1182\/blood-2008-11-190421","article-title":"Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.","volume":"113","author":"Lundqvist","year":"2009","journal-title":"Blood"},{"key":"2019111807502723300_B9","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.4049\/jimmunol.181.5.3449","article-title":"Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.","volume":"181","author":"Pegram","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"2019111807502723300_B10","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1182\/blood-2002-06-1751","article-title":"Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.","volume":"101","author":"Edinger","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111807502723300_B11","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity.","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"issue":"21","key":"2019111807502723300_B12","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1182\/blood-2009-05-222190","article-title":"NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.","volume":"115","author":"Olson","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111807502723300_B13","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nm915","article-title":"CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after BM transplantation.","volume":"9","author":"Edinger","year":"2003","journal-title":"Nat Med"},{"issue":"13","key":"2019111807502723300_B14","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1093\/emboj\/17.13.3714","article-title":"Hoxa9 transforms primary BM cells through specific collaboration with Meis1a but not Pbx1b.","volume":"17","author":"Kroon","year":"1998","journal-title":"EMBO J"},{"issue":"18","key":"2019111807502723300_B15","doi-asserted-by":"crossref","first-page":"7800","DOI":"10.1158\/0008-5472.CAN-10-1681","article-title":"Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth.","volume":"70","author":"Teng","year":"2010","journal-title":"Cancer Res"},{"issue":"8","key":"2019111807502723300_B16","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1182\/blood-2003-06-2125","article-title":"Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8 T cells.","volume":"103","author":"Verneris","year":"2004","journal-title":"Blood"},{"key":"2019111807502723300_B17","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ni.2046","article-title":"Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8(+) T cell responses during chronic infection.","volume":"12","author":"Kao","year":"2011","journal-title":"Nat Immunol"},{"issue":"5","key":"2019111807502723300_B18","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.4049\/jimmunol.0804268","article-title":"Tissue-specific homing and expansion of donor NK cells in allogeneic BM transplantation.","volume":"183","author":"Olson","year":"2009","journal-title":"J Immunol"},{"key":"2019111807502723300_B19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.4049\/jimmunol.176.3.1582","article-title":"CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer.","volume":"176","author":"Smyth","year":"2006","journal-title":"J Immunol"},{"key":"2019111807502723300_B20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-065X.2006.00445.x","article-title":"The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.","volume":"214","author":"Ghiringhelli","year":"2006","journal-title":"Immunol Rev"},{"issue":"18","key":"2019111807502723300_B21","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/blood-2009-03-208181","article-title":"Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.","volume":"114","author":"Zhou","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111807502723300_B22","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.immuni.2007.04.017","article-title":"Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor.","volume":"27","author":"Yamaguchi","year":"2007","journal-title":"Immunity"},{"issue":"9","key":"2019111807502723300_B23","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2004-03-1110","article-title":"From the bench to the bedside: ways to improve rituximab efficacy.","volume":"104","author":"Cartron","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111807502723300_B24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni1581","article-title":"Up on the tightrope: natural killer cell activation and inhibition.","volume":"9","author":"Lanier","year":"2008","journal-title":"Nat Immunol"},{"key":"2019111807502723300_B25","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.4049\/jimmunol.176.3.1517","article-title":"CD27 dissects mature NK cells into two subsets with distinct responsiveness and migratory capacity.","volume":"176","author":"Hayakawa","year":"2006","journal-title":"J Immunol"},{"issue":"8","key":"2019111807502723300_B26","doi-asserted-by":"crossref","first-page":"4764","DOI":"10.4049\/jimmunol.178.8.4764","article-title":"NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation.","volume":"178","author":"Huntington","year":"2007","journal-title":"J Immunol"},{"issue":"6","key":"2019111807502723300_B27","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.4049\/jimmunol.168.6.2585","article-title":"Cutting edge: inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells.","volume":"168","author":"Robbins","year":"2002","journal-title":"J Immunol"},{"issue":"2","key":"2019111807502723300_B28","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4049\/jimmunol.172.2.864","article-title":"Turnover and proliferation of NK cells in steady state and lymphopenic conditions.","volume":"172","author":"Jamieson","year":"2004","journal-title":"J Immunol"},{"issue":"12","key":"2019111807502723300_B29","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.4049\/jimmunol.180.12.8004","article-title":"T-bet plays a key role in NK-mediated control of melanoma metastatic disease.","volume":"180","author":"Werneck","year":"2008","journal-title":"J Immunol"},{"issue":"4","key":"2019111807502723300_B30","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1074-7613(04)00076-7","article-title":"T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells.","volume":"20","author":"Townsend","year":"2004","journal-title":"Immunity"},{"issue":"5647","key":"2019111807502723300_B31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.1090148","article-title":"Control of effector CD8+ T cell function by the transcription factor Eomesodermin.","volume":"302","author":"Pearce","year":"2003","journal-title":"Science"},{"issue":"1","key":"2019111807502723300_B32","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood-2005-08-027979","article-title":"Deficient expression of NCR in NK cells from acute myeloid leukemia: Evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction.","volume":"109","author":"Fauriat","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111807502723300_B33","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1172\/JCI45816","article-title":"Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity.","volume":"121","author":"Mamessier","year":"2011","journal-title":"J Clin Invest"},{"issue":"6","key":"2019111807502723300_B34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion.","volume":"131","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"issue":"10","key":"2019111807502723300_B35","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri3044","article-title":"NK cell development, homeostasis and function: parallels with CD8+ T cells.","volume":"11","author":"Sun","year":"2011","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"2019111807502723300_B36","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"issue":"20","key":"2019111807502723300_B37","doi-asserted-by":"crossref","first-page":"8437","DOI":"10.1158\/0008-5472.CAN-08-1440","article-title":"Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands.","volume":"68","author":"Wendel","year":"2008","journal-title":"Cancer Res"},{"issue":"21","key":"2019111807502723300_B38","first-page":"7468","article-title":"Fractalkine mediates natural killer-dependent antitumor responses in vivo.","volume":"63","author":"Lavergne","year":"2003","journal-title":"Cancer Res"},{"issue":"9","key":"2019111807502723300_B39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/ni1239","article-title":"Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.","volume":"6","author":"Oppenheim","year":"2005","journal-title":"Nat Immunol"},{"issue":"7","key":"2019111807502723300_B40","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood-2007-07-100057","article-title":"Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways.","volume":"111","author":"Coudert","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111807502723300_B41","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ni.1849","article-title":"\u201cUnlicensed\u201d natural killer cells dominate the response to cytomegalovirus infection.","volume":"11","author":"Orr","year":"2010","journal-title":"Nat Immunol"},{"issue":"5887","key":"2019111807502723300_B42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.1159806","article-title":"Anomalous type 17 response to viral infection by CD8+ T cells lacking T-bet and eomesodermin.","volume":"321","author":"Intlekofer","year":"2008","journal-title":"Science"},{"issue":"9","key":"2019111807502723300_B43","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1084\/jem.20070841","article-title":"Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells.","volume":"204","author":"Intlekofer","year":"2007","journal-title":"J Exp Med"},{"issue":"2","key":"2019111807502723300_B44","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.immuni.2011.07.009","article-title":"MicroRNA-29 regulates T-box transcription factors and interferon-\u03b3 production in helper T cells.","volume":"35","author":"Steiner","year":"2011","journal-title":"Immunity"},{"issue":"9","key":"2019111807502723300_B45","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/ni.1774","article-title":"Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.","volume":"10","author":"Zhou","year":"2009","journal-title":"Nat Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5758\/1497249\/zh802412005758.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/24\/5758\/1497249\/zh802412005758.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T08:04:24Z","timestamp":1574064264000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/24\/5758\/30322\/Rapid-development-of-exhaustion-and-downregulation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":45,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2012,6,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-03-415364","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]}}}